A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer

Trial Profile

A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs ARQ 761 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 13 Oct 2015 Planned initiation date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 13 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jul 2015 to 1 Sep 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top